Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 8 USA GLP-1 NBRX market share OzempicⓇ is now launched in seven countries leading to market share gains and expansion of the GLP-1 markets Canada GLP-1 NBRX Denmark GLP-1 volume market share market share NN GLP-1 VictozaⓇ OzempicⓇ dulaglutide exenatide albiglutide Weekly Monthly Weekly unit NBRX share NBRX share share 50% 100% 100% 45.1% 92.2% 79.8% 40% 80% 80% 40.2% 77.4% 30% 25.3% 60% 60% 45.6% 20% 19.9% 40% 40% 34.3% 14.5% 10% 20% 20% 14.8% 7.2% 19.8% 0% 0% 0% Jan 2018 Oct 2018 Jan 2018 July Jan 2018 2018 Oct 2018 Source: NBRX-IQVIA LRX Weekly, week ending 12 October 2018 OzempicⓇ has been launched in: the USA, Canada, Denmark, Switzerland, Ireland, Sweden and the Netherlands Source: NBRX-IQVIA monthly, July 2018 Source: Local sales data - Dansk lægemiddels information market intelligence, week ending 14 October 2018

View entire presentation